Entera Bio (ENTX) Non Operating Income (2019 - 2026)
Entera Bio's (ENTX) quarterly Non Operating Income came in at $34000.0 in Q1 2026, up 950.0% YoY from $3238.1 in Q1 2025, and up 30.77% on a QoQ basis from $26000.0 in Q4 2025.
Entera Bio (ENTX) Non Operating Income (2019 - 2026) Analysis & Trends
Entera Bio (ENTX) has 8 years of Non Operating Income data on file, last reported at $34000.0 in Q1 2026.
- Quarterly Non Operating Income rose 950.0% year-over-year to $34000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128000.0 (up 1322.22% YoY) and the FY2025 annual result came in at $90000.0, up 55.17% from the prior year.
- Non Operating Income climbed to $34000.0 in Q1 2026, from $26000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $60000.0 in Q2 2022 to a low of -$32000.0 in Q4 2023.
- A 5-year average of $18500.0 and a median of $21000.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income plunged 146.15% — and 2026, when it jumped 950.0%.
- Tracing ENTX's Non Operating Income over 5 years: stood at -$13000.0 in 2022, then plunged by 146.15% to -$32000.0 in 2023, then soared by 78.12% to -$7000.0 in 2024, then jumped by 471.43% to $26000.0 in 2025, then soared by 30.77% to $34000.0 in 2026.
- The last three Non Operating Income figures came in at $34000.0 (Q1 2026), $26000.0 (Q4 2025), and $56000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | -2.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.75 Mn |
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 26,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -7,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 45,000.00 |
| Dec 31, 2023 | -32,000.00 |
| Sep 30, 2023 | 36,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 22,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | -8,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Dec 31, 2021 | -27,000.00 |
| Sep 30, 2021 | -7,000.00 |
| Jun 30, 2021 | -24,000.00 |